Prostate Cancer

"[Although] American Indian/Alaskan Native patients do present with more advanced prostate cancer, show lower rates of definitive treatment, and higher mortality, once we adjust for some of these disparities in access, we found that there were no significant differences in mortality," says Carissa E. Chu, MD.

Expert insight on selection of androgen deprivation therapy and how related adverse events may be communicated to patients in advance.

Urologist David Morris, MD, FACS, shares his perspective on communicating cardiovascular risk to patients starting androgen deprivation therapy.

Urologist David Morris, MD, FACS, shares his perspective on communicating cardiovascular risk to patients starting androgen deprivation therapy.

Insight is provided on strategies that may be employed to mitigate cardiovascular risk in patients receiving care for prostate cancer.

“Metastatic castration-resistant prostate cancer remains a lethal disease, with high unmet needs in terms of treatment options, particularly for patients with BRCA1/2 gene mutations,” said Elena, MD, PhD

The application is supported by findings from the phase 3 MAGNITUDE study.

Immunotherapy utilization and costs accounted for 84% of the net increase in Medicare Part B payments, yet the treatment was administered to fewer than 20% of patients.

The addition of pembrolizumab to enzalutamide and ADT did not extend survival or delay disease progression compared with enzalutamide and ADT alone.

Expert perspectives on the typical patient workup that occurs in oncology practice to identify cardiovascular risk.

Cardiologist Anees A. Daud, MD, elucidates examinations and tests that help to identify cardiovascular risk in practice.

Medical oncologist Joelle Hamilton, MD, reflects on the prevalence of cardiovascular risk while managing prostate cancer in patients.

Direct insight from a cardiologist on the advent of cardiovascular risk when treating a patient for prostate cancer.

Cleveland Clinic highlights its use of irreversible electroporation, also known as Nanoknife, in select patients with prostate cancer.

Yale School of Medicine Associate Professor of Urology Michael Leapman, MD, MHS, and coauthors estimated the environmental impacts of prostate MRI and prostate biopsy.

"We found a sizeable and statistically significant uptick in compliance with genetic testing and compliance with post-test genetic counseling in patients who underwent testing after the implementation of the standardized protocol," says Siddharth Ramanathan.

"It will only be when the indications for focal therapy are expanded to higher-grade and larger tumors that we will begin to learn about the true efficacy of this approach," writes Badar M. Mian, MD.

Treatment with rucaparib reduced risk of imaging-based progression or death by half in men with BRCA-altered metastatic castration-resistant prostate cancer.

The combination use of niraparib plus abiraterone and prednisone continued to improve outcomes in patients with metastatic, castration-resistant prostate cancer and HRR gene alterations.

Expert perspectives on strategies to optimize communication, both between healthcare professionals and with patients who present with prostate cancer.

Cardiologist Anees A. Daud, MD, breaks down the typical patient with prostate cancer seen at his practice.

Urologist David Morris, MD, FACS, defines the typical patient with prostate cancer treated at his practice.

Oncologist Joelle Hamilton, MD, shares her perspective on the typical patient with prostate cancer seen at her institution.

Centering focus on a patient case of cardiovascular risk and prostate cancer, experts share their perspective on management strategies.

Comprehensive insight regarding strategies to mitigate cardiovascular risk in patients on therapy for prostate cancer.

Shared insight on a timeline of clinical studies contextualizing cardiovascular disease in the setting of prostate cancer management.

Expert perspectives on the risk of cardiovascular disease as it exists in the context of androgen deprivation therapy (ADT) and prostate cancer.

"We found that if the patient has normal IsoPSA, he has only 1% of risk of developing clinically significant prostate cancer in a median follow-up time of 18 months," says Nour Abdallah, MD.

The GPS test uses a 17-gene signature to predict disease aggressiveness and help guide treatment decisions for patients with localized prostate cancer.

"The reason that we really focus on prostate cancer is because it's amenable to early screening. Early detection is key in cure," says Janet Kukreja, MD, MPH, FACS.